OP-ED

FDA Should Add a Comparative Effectiveness Arm to Final Trials

The Food and Drug Administration’s Prescription Drug User Fee Act is up for reauthorization next year, and so is the consumer and drug industry face-off over the contentious issue of comparative effectiveness research (CER). Consumers, patients and some physicians are demanding that CER be required of all new drugs coming to market when there are already FDA-approved therapies for the same condition. They say it will give payers and patients immediate feedback on the relative worth of the latest drugs, which are always more pricey than what preceded them, especially if the older drugs are coming off patent.

Industry opposes including CER arms in final efficacy trials. The companies claim it will place additional costs on the already expensive new drug development process; provide inadequate information for actually divining the relative worth of two competing therapies; and dissuade companies from investing in follow-on drug research, which can turn up drugs that are significantly better than older drugs.

The American Enterprise Institute’s Scott Gottlieb, who served in the FDA during the Bush administration, this week offered a lengthy brief in support of the industry position. Unfortunately, he sets up a straw man in order to knock down what could be a very effective tool for lowering the cost of medicine. It behooves industry leaders to ignore his advice, and to ignore the bleating of their marketing departments’ incessant demand for follow-on drugs.

 

Requiring comparative arms in Phase III trials in situations where it is appropriate will encourage companies to channel their scarce research-and-development dollars into more medically significant opportunities – therapies for previously untreatable conditions or better drugs where the current options are inadequate. A CER requirement at FDA could go a long way toward turning around the sharp decline in drug industry innovation that has occurred over the past decade.

Phase III trials are also the right time to carry out CER from a societal perspecctive. Physicians and patients are demanding this information, not only because of cost concerns but because they very often they don’t know what works best. The Affordable Care Act created the Patient Centered Outcomes Research Institute and gave it a half billion dollars a year to carry out CER. Given the hundreds of competing therapies that were developed over the last half century when there was no comparative research, PCORI already has a lot on its plate. It makes no sense to add to its burden by not collecting information about the relative medical value of future drugs. The drug development process is when CER is the easiest and cheapest to carry out, since it only requires adding one more arm to an already planned trial — not starting all over from scratch as government-funded CER will have to do.

Gottlieb claims consumers and patient advocates are demanding that “new medicines should demonstrate that they offer clear advantages over older, often cheaper drugs” before they are approved. Some may say that, but it’s a red herring. The FDA standard now for efficacy is that a new drug has to be better than nothing; in other words, it must be tested against placebo (unless it is for a life-threatening condition where there is already an approved therapy on the market; then the new therapy must be tested against that therapy, or added to it, because denying the already-approved therapy in a placebo arm in a trial would be unethical).

I do not support the position of advocates like former New England Journal of Medicine editor Marcia Angell who think new drugs should have to be proven better than what exists before they are approved. If companies want to bring comparable therapies to market, that’s their business. It may even be the case that some me-too drugs work in some sub-populations, but not in others. So if one drug fails to achieve lower cholesterol, or offer arthritis pain relief, for instance, the doctor can switch her patient to the newer drug. But if the new drug is not proven to be better than what exists in a large Phase III trial, then physicians, patients and payers will have the information they need to insist that people start on the cheapest, comparably effective medicine that is available. For most drug classes, that will mean a generic.

These non-inferiority trials do not have to be inordinately more expensive. If companies do not opt to try to prove superiority, it only requires adding a third similarly-sized arm to the final trials. While this could in theory add close to 50 percent to the cost of a final trial (going from two arms to three arms), it won’t require exponentially larger arms since they’re not trying to prove superiority. PCORI could even consider allowing companies to apply for grants to underwrite the comparative arm in a new drug trial. If it is in a therapeutic class or for a condition that the new agency has deemed important, adding the comparative arm or arms to a trial that was largely industry-funded would be substantially cheaper for the government than starting over from scratch.

A word of caution is in order before the FDA requires comparative arms in non-inferiority trials for new drugs. If the condition isn’t life-threatening, it should still require a placebo arm or insist on an adequately sized trial to avoid the “dumbing down” of new drugs. That has been a problem in the antibiotics field, where a succession of non-inferiority trials without placebo arms may have created a situation where new drugs have been approved even though their efficacy is in doubt. This is a fluke of statistics where each succeeding drug is near the bottom of the band that defines statistically significant non-inferiority. Adequately-sized trials with clear endpoints can usually avoid this problem.

Merrill Goozner has been writing about economics and health care for many years. The former chief
economics correspondent for the Chicago Tribune, Merrill has written for a long list of publications including
the New York Times, The American Prospect, The Washington Post and Financial Times. You can read more
pieces by him at GoozNews, where this post first appeared.

Livongo’s Post Ad Banner 728*90

33
Leave a Reply

32 Comment threads
1 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
26 Comment authors
MackenzieGracekitchen and bathroom remodeling costsJesusVictoria Recent comment authors
newest oldest most voted
Mackenzie
Guest

Have you got any experience? duration grandson paxil xanax same yellow International Development Secretary Justine Greening said: ” Rangoon General Hospital has offered life-saving healthcare to the Burmese people for generations and it is right that we help Aung San Suu Kyi in her work to restore this crucial institution.

Grace
Guest

Where are you calling from? david grow lexapro label bodies Gordon Jones, the Atlanta History Center’s senior military historian and curator, said it could have been fired by federal soldiers from outside the city in an effort to strike the Confederate’s Railroad Roundhouse, a key military target in the general area where the device was found.

kitchen and bathroom remodeling costs
Guest

certainly like your web site however you have to test the spelling on quite a few of youir posts.
Many of them are rife with spelling problems and I find it very bothersome to inform
the truth however I’ll certainly coome again again.

Also visit my webpage kitchen and bathroom remodeling costs

Jesus
Guest

Very Good Site http://www.mypostpartumvoice.net/hotel-cash-advance/ cash advance hurt credit Tom W-C. Summary of 2006 AHA/ACC secondary prevention recommendations for patients with

Victoria
Guest

Could you send me an application form? clomid price in india Example Expectations: Commitment to Excellence

Maya
Guest

My battery’s about to run out http://www.mamaloca.net/ditropan/ buy ditropan 2nd Prescription – variable variable O Fields and format are the same

Mary
Guest

I’m self-employed http://www.porlainfancia.com/quanto-costa-il-cialis-20-mg/ quanto costa il cialis 20 mg IN THE FEATURED LINKS SECTION. DETAILED INSTRUCTIONS WILL ALSO BE FOUND THERE.

Robert
Guest

Could I have a statement, please? http://www.mamaloca.net/ditropan/ order ditropan outside contamination of the primary container occurs, the primary container must be placed

Genesis
Guest

How many days will it take for the cheque to clear? http://www.goedkoopstemotorverzekeringberekenen.nl/illegal-buy-viagra-online-usa/ Legit Place To Buy Viagra Online 12.0 Rx DENIAL CODES – TABLE 7. 12.0.1

Tommy
Guest

How many more years do you have to go? http://www.henclick.com/cheap-pfizer-viagra-online/ cheap pfizer viagra online (Name of Authority issuing Passport/ Travel Document)

bonser
Guest

I’m on work experience http://www.kirnberger.com/provera/ purchase provera Issues not addressed here or in other official course documents will be resolved according to

Dominic
Guest

What part of do you come from? http://discoveri.in/viagra-50-mg-cost/ Pfizer Viagra Price In India 1.3. Formulate evidence-4. Develop a patient-centered, · Identify health Complete 4 MTM patient case

Claire
Guest

I want to report a http://www.valvomo.fi/cheap-cialis-india/ Viagra Cialis Purchase documented on the hard copy of the prescription for auditing purposes. A PerformRx

steep777
Guest

An accountancy practice http://colheradacultural.com.br/aciphex/ buy aciphex online • Seeming lack of genuinely concerned friends

Nevaeh
Guest

Where’s the postbox? http://www.goedkoopstemotorverzekeringberekenen.nl/illegal-buy-viagra-online-usa/ Buy Cheapest Generic Viagra users. CSC is the eMedNY contractor and is responsible for its operation.